Payment overview · 2025
General Payments
$794.87
44 reported records · 18 companies
Healthcare provider profile · identity verified
James David Rowley, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SIERRA VISTA, AZ · NPI 1053806042
Verified facts
What the public records show
CMS Open Payments records show James David Rowley, FNP received $794.87 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Belbuca by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $193.72 | 24.4% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $104.99 | 13.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.92 | 11.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $88.83 | 11.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.96 | 7.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.15 | 5.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.16 | 4.0% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.66 | 2.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.21 | 2.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.04 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.48 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.24 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.74 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.70 | 2.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $16.15 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.21 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.01 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.70 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $794.87 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.65 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $104.99 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.74 | 4 | 2025 |
Source payment records
|
|||||
| BYETTA Normalized: byetta |
Drug | AstraZeneca Pharmaceuticals LP | $59.36 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.28 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $55.96 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.15 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 105 |
| Losartan Potassium | Losartan Potassium | 340 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 72 |
| Gabapentin | Gabapentin | 161 | 48 |
| Lisinopril | Lisinopril | 159 | 49 |
| Omeprazole | Omeprazole | 159 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 40 |
| Metformin Hcl Er | Metformin Hcl | 141 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 132 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 34 |
| Trazodone Hcl | Trazodone Hcl | 106 | 28 |
| Furosemide | Furosemide | 98 | 32 |
| Tramadol Hcl | Tramadol Hcl | 92 | 32 |
| Sertraline Hcl | Sertraline Hcl | 90 | 24 |
| Potassium Chloride | Potassium Chloride | 88 | 24 |
| Eliquis | Apixaban | 85 | 20 |
| Alprazolam | Alprazolam | 83 | 13 |
| Farxiga | Dapagliflozin Propanediol | 83 | 20 |
| Prednisone | Prednisone | 83 | 53 |
| Donepezil Hcl | Donepezil Hcl | 82 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | suppressed |
| Simvastatin | Simvastatin | 77 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 24 |
| Lorazepam | Lorazepam | 75 | 18 |
| Azithromycin | Azithromycin | 72 | 54 |
| Alendronate Sodium | Alendronate Sodium | 67 | 23 |
| Bupropion Xl | Bupropion Hcl | 66 | 19 |
| Clonazepam | Clonazepam | 66 | 13 |
| Pregabalin | Pregabalin | 66 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 15 |
| Metformin Hcl | Metformin Hcl | 63 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 21 |
| Famotidine | Famotidine | 57 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 23 |
| Allopurinol | Allopurinol | 55 | 15 |
| Ozempic | Semaglutide | 53 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 21 |
| Mirtazapine | Mirtazapine | 51 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 44 |
| Diazepam | Diazepam | 50 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 17 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 16 |
| Montelukast Sodium | Montelukast Sodium | 46 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 20 |
| Meloxicam | Meloxicam | 45 | 18 |
| Ibuprofen | Ibuprofen | 44 | 24 |
| Carvedilol | Carvedilol | 41 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 11 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 33 |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 33 |
| Spironolactone | Spironolactone | 36 | 14 |
| Celecoxib | Celecoxib | 34 | 12 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Mupirocin | Mupirocin | 22 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 17 |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Prolia | Denosumab | 17 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Torsemide | Torsemide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $794.87 · 44 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEYFORTUS, BREZTRI, BYETTA, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, MENQUADFI, MOUNJARO, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, REPATHA, ROTATEQ, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VAXELIS, VAXNEUVANCE, VRAYLAR, VYEPTI, XIFAXAN, XTAMPZA, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error